Seles’ first symptoms appeared suddenly around three years ago. She began having double vision and weakness in her arms and ...

New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Women with myasthenia gravis have higher rates of preterm birth and cesarean delivery, new findings show, underscoring the need for careful pregnancy management and monitoring.

Results from the phase III VIBRANCE-MG study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that nipocalimab (Imaavy) was safe and ...

They were just going to the movies. But the theater was way too hot. By the time they left, he couldn’t even hold his head up. He couldn’t speak. And he certainly couldn’t walk. “Fortunately, I had my ...

Myasthenia gravis (MG) doesn’t have a cure. But with treatment, most people manage the condition well. Medications, surgeries, and other procedures can help. It may take time to find what works best ...

ATLANTA, Oct. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the opening of applications for the second annual UCB U.S. Myasthenia Gravis Scholarship™, supporting ...

Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a ...

Purpose Myasthenia gravis can cause variable strabismus with disabling diplopia and/or poor cosmesis. A retrospective study of a group of patients with myasthenia gravis or ‘myasthenia gravis like’ ...

KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With ...

Argenx (ARGX) announced the presentation of new data further highlighting the efficacy and safety of Vyvgart across generalized myasthenia gravis patient populations. The Phase 3 ADAPT SERON study met ...